Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Busin...(mation of the use of the NEP2320 PCT Sys...),Health

Mr. Schumacher concluded: "We continue to believe that we have developed the 'best-in-class' sample preparation system available today, one that we believe offers significant advantages in a number of key areas -- including safety, speed, versatility, reproducibility, and quality -- to the estimated 390,000 scientists worldwide who extract DNA, RNA, proteins, and small molecules in their research studies. Combined with a new sales team of seven ambitious and experienced personnel, strong collaborations, and emerging market penetration, we believe that we are well poised to finish the year strong and to enter 2008 with our resources squarely focused on continuing and expanding our commercialization efforts."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Financial Teleconference and Web-cast

As announced on November 8, 2007, the Company will host a teleconference at 4:30 pm EST on Monday November 12, 2007 to discuss its third quarter financial results and to provide a business update.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predicti
'/>"/>